Amgen's Cholesterol Drug Patents Are Valid, Jury Says
Patents related to Amgen Inc.'s cholesterol-lowering drug Repatha survived a challenge by rival pharmaceutical company Sanofi when a Delaware federal jury found largely in Amgen's favor Monday....To view the full article, register now.
Already a subscriber? Click here to view full article